3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
3 - 23andMe Holding Co. (0001804591) (Issuer)
S-1 - 23andMe Holding Co. (0001804591) (Filer)
8-K/A - 23andMe Holding Co. (0001804591) (Filer)
8-K - 23andMe Holding Co. (0001804591) (Filer)
CERT - VG Acquisition Corp. (0001804591) (Filer)
25 - VG Acquisition Corp. (0001804591) (Filer)
8-K - VG Acquisition Corp. (0001804591) (Filer)
8-K - VG Acquisition Corp. (0001804591) (Filer)
425 - VG Acquisition Corp. (0001804591) (Subject)
10-Q - VG Acquisition Corp. (0001804591) (Filer)
425 - VG Acquisition Corp. (0001804591) (Subject)
Record Year-to-Date Total Debt and Equity Commitments of $971.7 Million Record Year-to-Date Total Fundings of $634.0 Million Surpassed $12.0 Billion in Cumulative Total Debt Commitments since Inception Q2 2021 Net Asset Value per Share Increased 3.1% to $11.71 from Q1 2021 Record Undistributed Earnings Spillover of $160.2 Million, or $1.38(1) per Ending Shares Outstanding Q2 2021 Financial Achievements and Highlights Net Investment Income "NII" of $37.0 million, or $0.32 per share, an increase of 3.6% year-over-year Total Investment Income of $69.6 million, an increase of 2.3% year-over-year Total gross new debt and equity commitments of $440.8 million Net Hercules' debt and e
SUNNYVALE, Calif. and NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) -- 23andMe, Inc., a leading consumer genetics and research company, and VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced the completion of their previously announced business combination. The transaction, which was approved on June 10, 2021 by VG Acquisition Corp.'s shareholders, uniquely positions 23andMe to revolutionize personalized healthcare and therapeutic development through human genetics. The combined company is called 23andMe Holding Co. and will be traded on The Nasdaq Global Select Market ("Nasdaq") beginning on June 17, 2021 under the new ticker symb
NEW YORK, June 10, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE: VGAC), a special purpose acquisition company sponsored by Virgin Group ("VGAC" or the "Company") today announced that its shareholders voted to approve the previously announced merger agreement with 23andMe, Inc. ("23andMe") at VGAC's extraordinary general meeting of shareholders (the "Special Meeting") held earlier today. More than 87% of the votes cast at the Special Meeting were in favor of the approval of the merger agreement. VGAC shareholders also voted overwhelmingly to approve the other proposals presented at the Special Meeting. As previously announced, the consummation of the business combination with 23andMe is
NEW YORK and SUNNYVALE, Calif., June 2, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group ("VGAC" or the "Company"), reminds its shareholders to vote on the Company's proposed business combination with 23andMe, Inc. ("23andMe"), a leading consumer genetics and research company, and the related proposals that will come before VGAC's extraordinary general meeting of shareholders (the "Special Meeting"). The VGAC board unanimously recommends that shareholders vote "FOR" the business combination and the other proposals that will come before the Special Meeting. The Special Meeting is scheduled for June 10, 2021 at 10:00 a.m. ET
SUNNYVALE, Calif., June 2, 2021 /PRNewswire/ -- 23andMe Inc., a leading consumer genetics and research company, today announced that D. Wade Walke, Ph.D. will join the company as Vice President of Investor Relations. Earlier this year, 23andMe entered into a definitive merger agreement with VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group, to become a publicly-traded company. Walke will be responsible for demonstrating 23andMe's vision and long-term value with its shareholders and the financial community as the company transitions to the public markets.
NEW YORK, May 28, 2021 /PRNewswire/ -- VG Acquisition Corp. (the "Company") today announced it received a notice on May 25, 2021 from the New York Stock Exchange ("NYSE") indicating that as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the "Quarterly Report"), the Company no longer complies with the continued listing requirements set forth in Section 802.01E of the NYSE Listed Company Manual. The notice has no immediate impact on the listing of the Company's securities, which will continue to trade on the NYSE, subject to the Company's compliance with other applicable continued listing requirements. As previously disc
NEW YORK and SUNNYVALE, Calif., May 26, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE:VGAC) ("VGAC" and, after the Domestication (as defined below) and following its name change to 23andMe Holding Co., "New 23andMe") today announced that, upon the Domestication and the consummation of its pending business combination (the "Business Combination") with 23andMe, Inc. ("23andMe"), New 23andMe Class A Common Stock and New 23andMe Warrants (each as defined below) will be listed on The Nasdaq Global Select Market ("Nasdaq"). The decision to list on Nasdaq was made in connection with the Business Combination and enables the combined company to be listed alongside other innovative companies that ar
NEW YORK and SUNNYVALE, Calif., May 17, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced that the date of its extraordinary general meeting of shareholders to vote on its proposed business combination with 23andMe, Inc., a leading consumer genetics and research company, will be June 10, 2021. Shareholders of record as of the close of business on May 5, 2021 are entitled to vote on matters that come before the extraordinary general meeting. The business combination, if approved by VGAC's stockholders, is expected to close as soon as practicable following the extraordinary general meeting. Upon the closing,
NEW YORK and SUNNYVALE, Calif., May 5, 2021 /PRNewswire/ -- VG Acquisition Corp. (NYSE:VGAC), a special purpose acquisition company sponsored by Virgin Group, today announced that it has filed an amended registration statement on Form S-4 in connection with its pending business combination with 23andMe, Inc., a leading consumer genetics and research company. The Amended S-4 includes restated financial statements of VGAC for its fiscal year ended December 31, 2020 in order to account for its outstanding warrants as liabilities in accordance with applicable accounting rules and recent guidance from the Securities and Exchange Commission (SEC). It also updates the information about 23andMe to
Record Q1 Gross New Debt and Equity Commitments of $530.9 Million Q1 2021 Net Asset Value "NAV" per Share Increased 0.9% to $11.36 from Q4 2020 Strong Available Liquidity of $550.0 Million Record Undistributed Earnings Spillover of $109.1 Million, or $0.94(1) per Ending Shares Outstanding Declared a $0.28 Supplemental Distribution for Fiscal 2021 Payable over Four Quarters beginning with Q1 2021 Q1 2021 Financial Achievements and Highlights Net Investment Income "NII" of $34.6 million, or $0.30 per share Total Investment Income of $68.8 million Total gross new debt and equity commitments of $530.9 million Net Hercules' debt and equity commitments of $467.2 million(2) Total
SC 13G - 23andMe Holding Co. (0001804591) (Subject)
SC 13D - 23andMe Holding Co. (0001804591) (Subject)
SC 13G - VG Acquisition Corp. (0001804591) (Subject)
SC 13G - VG Acquisition Corp. (0001804591) (Subject)
SC 13G/A - VG Acquisition Corp. (0001804591) (Subject)
SC 13G - VG Acquisition Corp. (0001804591) (Subject)